Abstract: A stator for an electric drive unit, in particular an electric motor, and to a method for the production thereof. The stator for the electric drive unit comprises a stator core having at least one stator pole; a stator winding which forms all coils from a continuous winding wire; at least one insulating cap, on which a plurality of contact receiving pockets are arranged for receiving the winding wire; a number of deflection domes which are distributed on the outer lateral surface of the cap; and wire guiding contours at the outer lateral surface of the insulting cap for spacing the winding wire; wherein the plurality of contact receiving pockets each have a receiving region for the winding wire which has a different design, and wherein the plurality of contact receiving pockets comprise at least one deflection balcony.

Abstract: The present invention relates to systems and methods for screening compounds and/or mutant ribosomal proteins in a eukaryotic cell that increase or decrease the translation of a target gene and thereby ameliorate or revert a defective and/or undesired translation of a target gene. Disclosed are compounds and proteins as identified with the methods and systems of the invention, pharmaceutical and cosmetic compositions thereof, their uses for the preparation of a medicament, methods of treatment of a disease or condition or cosmetic condition related to the defective translation of a gene, for example genetic diseases such as Epidermolysis bullosa, as well as diagnostic measures practical for the clinical evaluation of such diseases or conditions. Also, kits are provided which comprise the identified compounds and/or proteins in addition to suitable means for performing the methods of the invention.

Abstract: The present invention relates to systems and methods for screening compounds and/or mutant ribosomal proteins in a eukaryotic cell that increase or decrease the translation of a target gene and thereby ameliorate or revert a defective and/or undesired translation of a target gene. Disclosed are compounds and proteins as identified with the methods and systems of the invention, pharmaceutical and cosmetic compositions thereof, their uses for the preparation of a medicament, methods of treatment of a disease or condition or cosmetic condition related to the defective translation of a gene, for example genetic diseases such as Epidermolysis bullosa, as well as diagnostic measures practical for the clinical evaluation of such diseases or conditions. Also, kits are provided which comprise the identified compounds and/or proteins in addition to suitable means for performing the methods of the invention.

Abstract: The present invention relates to a process for the variable adjustment of the electrical insulation properties of varistor-containing composite materials with the aid of defined filler mixtures, to the use of such filler mixtures, and to composite materials having resistive and capacitive field-control properties comprising filler mixtures of this type.

Abstract: The invention describes anti-cancer therapies comprising using an LRP5 antagonist in combination with an anti-PD1 antibody, each as described herein.

Abstract: The present invention relates to a particulate filler which has a coating on support particles in each case surrounding the latter, which comprises a titanium dioxide doped with niobium and at least one further element, to a process for the preparation of a particulate filler of this type and to the use thereof, in particular as varistor filler having nonlinear electrical properties in coating compositions and moulding compounds.

Abstract: A cable fitting for cables that can be used for high-voltage direct-current (HVDC) energy transmission, the cable fitting having an electrically insulating layer. A process for the production of an electrically insulating layer of such a cable fitting, and also the use thereof.

Abstract: The invention describes anti-cancer therapies comprising using an polypeptide capable of specifically binding to LRP5 and LRP6 in combination with an anti-PD1 antibody, each as described herein.

Abstract: The invention describes anti-cancer therapies comprising using an LRP5 antagonist in combination with an anti-PD1 antibody, each as described herein.

Abstract: The present invention relates to a cable fitting for cables that can be used for high-voltage direct-current (HVDC) energy transmission, where the cable fitting has an electrically insulating layer, to a process for the production of an electrically insulating layer of such a cable fitting, and also to use thereof.

Abstract: The present invention relates to a pharmaceutical composition which includes naturally occurring, non-transgenic isolated bacteria from the group of Lactococcus and Acinetobacter or fragments thereof or mixtures thereof, to such a bacterium as a medicament for the prevention and/or treatment of allergic or chronic inflammatory disorders and to a process for producing this composition.

Abstract: The present invention relates to the isolation of recombinant and/or biotherapeutic proteins for capture or clarification from cell culture fluid using copolymers. The copolymers used according to the process of the present invention comprise hydrophobic and anionic residues.

Abstract: The present invention pertains to a novel pre-mRNA trans-splicing molecule (RTM) comprising a binding region which is complementary to a pre mRNA of a tumor associated gene, and a coding domain which encodes for a suicide gene. Specific embodiments of the present invention relate to RTMs which mediate trans-splicing of a suicide gene, such as thymidine kinase from herpes simplex virus (HSV-tk), with the pre mRNA of the squamous cell carcinoma associated gene solute carrier organic anion transporter family member 1B3 (SLCO1B3). The invention provides RTMs which selectively kill cells expressing SLCO1B3 and which are thus useful in the treatment of cancer, specifically squamous cell carcinoma associated with epidermolysis bullosa. Also provided are methods, kits and pharmaceutical compositions relating to the RTMs in accordance to the invention.

Abstract: The present invention relates to the isolation of recombinant and/or biotherapeutic proteins for capture or clarification from cell culture fluid using copolymers. The copolymers used according to the process of the present invention comprise hydrophobic and anionic residues.

Abstract: The present invention pertains to a novel pre-mRNA trans-splicing molecule (RTM) comprising a binding region which is complementary to a pre mRNA of a tumor associated gene, and a coding domain which encodes for a suicide gene. Specific embodiments of the present invention relate to RTMs which mediate trans-splicing of a suicide gene, such as thymidine kinase from herpes simplex virus (HSV-tk), with the pre mRNA of the squamous cell carcinoma associated gene solute carrier organic anion transporter family member 1B3 (SLCO1B3). The invention provides RTMs which selectively kill cells expressing SLCO1B3 and which are thus useful in the treatment of cancer, specifically squamous cell carcinoma associated with epidermolysis bullosa. Also provided are methods, kits and pharmaceutical compositions relating to the RTMs in accordance to the invention.

Abstract: The present invention relates to a composition for use in the prevention of the rejection of skin tissue, comprising an effective amount of a peptide comprising an epitope of an antigen selected from the group of the polypeptides type XVII collagen, VII collagen, integrin alpha 6, integrin beta 4, chains of laminin, chains of laminin 322, type IV collagen, plectin, plakoglobin, bullous pemphigoid antigen 1, periplakin, envoplakin, desmoglein 1, desmoglein 3, a desmocollin and human bullous pemphigoid antigen 2 (hBPAG2) wherein said epitope induces immunological tolerance against its underlying polypeptide, and/or a nucleic acid for expressing a peptide comprising an epitope of said antigen as well as a gene therapy based on the composition, in the context of autoimmune blistering diseases, such as bullous pemphigoid or genetic skin diseases such as epidermolysisbullosa.

Abstract: The present invention relates to specific and markedly improved pre-mRNA trans-splicing molecule (RTM) molecules which are designed to correct specific genes expressed within cells to be targeted, and which are associated with epidermolysis bullosa, cystic fibrosis, pachyonychia congenital, and psoriasis or neurodermitis, as well as cancers of the skin. In particular, the RTMs of the present invention are genetically engineered to interact with a specific target pre-mRNA expressed in cells to be targeted so as to result in correction of genetic defects or reprogramming of gene expression responsible for a variety of different skin disorders.

Abstract: The present invention relates to a method and kit for performing assays like immunoassays. The assays are performed by using two different types of magnetic beads.

Abstract: The present invention is directed to a animal feed for calves comprising calf-specific bacteria, optionally lipids, proteins, vitamins and/or mineral materials for conditioning of the intestinal flora in calves, and thus, for prophylaxis and/or treatment of diarrhea in calves.

Abstract: The present invention relates to specific and markedly improved pre-mRNA trans-splicing molecule (RTM) molecules which are designed to correct specific genes expressed within cells to be targeted, and which are associated with epidermolysis bullosa, cystic fibrosis, pachyonychia congenital, and psoriasis or neurodermitis, as well as cancers of the skin. In particular, the RTMs of the present invention are genetically engineered to interact with a specific target pre-mRNA expressed in cells to be targeted so as to result in correction of genetic defects or reprogramming of gene expression responsible for a variety of different skin disorders.